BUZZ-IceCure up after FDA panel backs use of its breast cancer treatment system

Reuters11-08
BUZZ-IceCure up after FDA panel backs use of its breast cancer treatment system

** Shares of Israel-based medical device maker IceCure Medical ICCM.O rise 8.11% to 79 cents premarket

** A panel of experts to the FDA supported the use of IceCure's system when used according to the proposed indications for the treatment of patients with a type of breast cancer

** ICCM's ProSense provides a minimally invasive treatment option to destroy tumors by freezing them

** 9 panelists voted in favor and 5 voted against the benefit-risk profile of the system

** FDA is not obligated to follow the panel's decision, but usually does

** Co expects FDA's decision by Q1 2025

** Up to last close, stock down ~31% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment